Search
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older.
Categories: Agents for Dermatitis, Excluding CorticosteroidsAncestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnAncestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal
Cystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnTwo molecules of cysteine are joined together by a disulfide bridge to form cystine.
Synonyms: (R,R)-3,3'-dithiobis(2-aminopropanoic acid)Sorbitol
go.drugbank.com/drugs/DB01638ApprovedInvestigationalIt was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures. … Sorbitol occurs naturally and is also produced synthetically from glucose.
Categories: Compounds used in a research, industrial, or household setting, Drugs for ConstipationPerampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalIt is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. … The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]
Categories: Agents for Dermatitis, Excluding CorticosteroidsDelandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigational[L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … Microdystrophin is a truncated, functional form of dystrophin.
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnIt was rejected for approval for use in the United States. … Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil.
Besilesomab
go.drugbank.com/drugs/DB13979ApprovedBesilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Human interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigationalIt is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012] … [A191784] Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.
Categories: Experimental Unapproved Treatments for COVID-19, Interferon Type I